Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB0001 versus timolol for intraocular pressure reduction in primary open-angle glaucoma or ocular hypertension
ACTRN12626001086358Phase 2Not yet recruiting
- Sponsor
- Tavo Biotherapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TB0001 in open-angle glaucoma (OAG) and ocular hypertension (4 arms), sponsored by Tavo Biotherapeutics. Primary endpoint: Change from baseline in mean diurnal intraocular pressure. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
TB0001
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on ACTRN12626001086358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001086358.